HRP20170531T1 - Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze - Google Patents
Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze Download PDFInfo
- Publication number
- HRP20170531T1 HRP20170531T1 HRP20170531TT HRP20170531T HRP20170531T1 HR P20170531 T1 HRP20170531 T1 HR P20170531T1 HR P20170531T T HRP20170531T T HR P20170531TT HR P20170531 T HRP20170531 T HR P20170531T HR P20170531 T1 HRP20170531 T1 HR P20170531T1
- Authority
- HR
- Croatia
- Prior art keywords
- terbinafine
- baclofen
- preparation
- use according
- sustained
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- 230000033115 angiogenesis Effects 0.000 title claims 2
- 238000013459 approach Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 10
- 229960002722 terbinafine Drugs 0.000 claims 10
- 229960000794 baclofen Drugs 0.000 claims 9
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims 4
- 229960000654 sulfafurazole Drugs 0.000 claims 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 3
- 229960003009 clopidogrel Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 3
- 229960000681 leflunomide Drugs 0.000 claims 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 3
- 229960003243 phenformin Drugs 0.000 claims 3
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 claims 2
- 229960002724 fenoldopam Drugs 0.000 claims 2
- 229960000901 mepacrine Drugs 0.000 claims 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Claims (12)
1. Pripravak koji sadrži baklofen ili terbinafin, ili njihove soli ili oblike s produljenim oslobađanjem, za uporabu u liječenju Alzheimerove bolesti.
2. Pripravak za uporabu prema zahtjevu 1, dalje sadrži barem jedan drugačiji dodatni spoj odabran iz grupe koju čine leflunomid, sulfizoksazol, terbinafin, baklofen, klopidogrel, fenoldopam, mepakrin i fenformin, ili njihove soli ili oblici s produljenim oslobađanjem, za istodobnu, odvojenu ili uzastopnu primjenu s baklofenom ili terbinafinom.
3. Pripravak za uporabu prema zahtjevu 2, gdje taj pripravak sadrži barem jednu od sljedećih kombinacija lijekova, ti lijekovi su u svakoj od ovih kombinacija za istodobnu, odvojenu ili uzastopnu primjenu:
- baklofen i sulfizoksazol,
4. baklofen i leflunomid,
5. terbinafin i sulfizoksazol,
6. terbinafin i leflunomid,
7. terbinafin i fenoldopam,
8. terbinafin i mepakrin,
9. terbinafin i fenformin,
10. terbinafin i klopidogrel,
11. baklofen i fenformin, ili
12. baklofen i klopidogrel.
4. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje taj pripravak dalje sadrži barem jedan lijek koji povećava angiogenezu, za istodobnu, odvojenu ili uzastopnu primjenu.
5. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje taj pripravak dalje sadrži farmaceutski prikladan nosač ili pomoćnu tvar.
6. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se primjena tog pripravka subjektu ponavlja.
7. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je subjekt čovjek.
8. Pripravak koji sadrži terbinafin i sulfizoksazol, ili njihove soli ili oblike s produljenim oslobađanjem, za istodobnu, odvojenu ili uzastopnu primjenu.
9. Baklofen, ili njegova sol ili oblik s produljenim oslobađanjem, za uporabu u liječenju Alzheimerove bolesti u ljudskog subjekta.
10. Baklofen, ili njegova sol ili oblik s produljenim oslobađanjem, za uporabu u zaštiti stanica od toksičnosti amiloid-beta peptida u ljudskog subjekta s Alzheimerovom bolešću.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4858308P | 2008-04-29 | 2008-04-29 | |
| PCT/EP2009/055205 WO2009133141A2 (en) | 2008-04-29 | 2009-04-29 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| EP09738185.9A EP2282778B1 (en) | 2008-04-29 | 2009-04-29 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170531T1 true HRP20170531T1 (hr) | 2017-06-16 |
Family
ID=41222690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170531TT HRP20170531T1 (hr) | 2008-04-29 | 2017-04-03 | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11291670B2 (hr) |
| EP (1) | EP2282778B1 (hr) |
| JP (1) | JP5721230B2 (hr) |
| KR (1) | KR101660401B1 (hr) |
| CN (1) | CN102065898B (hr) |
| AU (1) | AU2009242126B2 (hr) |
| BR (1) | BRPI0911520A2 (hr) |
| CA (1) | CA2722453C (hr) |
| CY (1) | CY1118956T1 (hr) |
| DK (1) | DK2282778T3 (hr) |
| EA (1) | EA021731B1 (hr) |
| ES (1) | ES2622504T3 (hr) |
| HR (1) | HRP20170531T1 (hr) |
| HU (1) | HUE033726T2 (hr) |
| IL (1) | IL208982B (hr) |
| LT (1) | LT2282778T (hr) |
| MX (1) | MX2010011881A (hr) |
| NZ (1) | NZ589307A (hr) |
| PL (1) | PL2282778T3 (hr) |
| PT (1) | PT2282778T (hr) |
| SI (1) | SI2282778T1 (hr) |
| WO (1) | WO2009133141A2 (hr) |
| ZA (1) | ZA201008037B (hr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| NZ589304A (en) * | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| EP2540297B1 (en) | 2008-11-19 | 2015-04-08 | Forum Pharmaceuticals Inc. | Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CN105837566B (zh) | 2010-05-17 | 2018-02-06 | 富瑞姆制药公司 | (R)‑7‑氯‑N‑(奎宁环‑3‑基)苯并[b]噻吩‑2‑甲酰胺盐酸盐单水合物的晶型 |
| EP2608782B1 (en) | 2010-08-24 | 2016-06-29 | Algiax Pharmaceuticals GmbH | Novel use of leflunomide and malononitrilamides |
| DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| EP2673363B1 (en) * | 2011-02-11 | 2017-08-23 | The Rockefeller University | Treatment of angiogenesis disorders |
| JP6430445B2 (ja) * | 2011-03-01 | 2018-11-28 | ファーネクストＰｈａｒｎｅｘｔ | バクロフェンおよびアカンプロセートに基づく神経疾患の治療 |
| US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| UA115968C2 (uk) | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| PL2560631T3 (pl) | 2011-03-01 | 2014-06-30 | Pharnext | Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
| AU2013224959B2 (en) * | 2012-03-01 | 2017-12-07 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| EP2705841A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| UA114811C2 (uk) * | 2013-02-28 | 2017-08-10 | Фарнекст | Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR101579008B1 (ko) * | 2013-09-25 | 2015-12-22 | 경북대학교 산학협력단 | ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EA201691602A1 (ru) | 2014-02-11 | 2017-03-31 | Фарнекст | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств |
| CN104928353A (zh) * | 2014-03-19 | 2015-09-23 | 上海吉凯基因化学技术有限公司 | 人dgkz基因的用途及其相关药物 |
| WO2016054083A1 (en) * | 2014-09-30 | 2016-04-07 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis |
| WO2016201086A1 (en) * | 2015-06-12 | 2016-12-15 | Rush University Medical Center | Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein |
| JP7027318B2 (ja) * | 2016-02-05 | 2022-03-01 | ファーネクスト | 神経障害の新規の併用療法 |
| WO2018096538A1 (en) * | 2016-11-23 | 2018-05-31 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity |
| AU2018258970B2 (en) | 2017-04-24 | 2021-07-15 | Pharnext | Idalopirdine-based combinatorial therapies of Alzheimer's disease |
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| EP3706867A4 (en) * | 2017-11-07 | 2021-08-11 | The Regents Of The University Of Michigan | THERAPEUTIC COMBINATION FOR TREATMENT OF CEREBELLIC ATAXIA |
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| WO2020111171A1 (ja) * | 2018-11-29 | 2020-06-04 | 雪印メグミルク株式会社 | 血管新生促進用組成物 |
| CN110806488B (zh) * | 2019-12-06 | 2020-09-25 | 南京医科大学 | Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用 |
| WO2023059867A1 (en) * | 2021-10-08 | 2023-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for treating or preventing alzheimer's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH072688A (ja) * | 1991-06-11 | 1995-01-06 | Rikomu:Kk | 腸内有毒腐敗産物抑制剤 |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ES2124800T3 (es) * | 1993-01-08 | 1999-02-16 | Hoechst Ag | Empleo de leflunomida para la inhibicion de interleuquina 1 beta. |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
-
2009
- 2009-04-29 MX MX2010011881A patent/MX2010011881A/es active IP Right Grant
- 2009-04-29 LT LTEP09738185.9T patent/LT2282778T/lt unknown
- 2009-04-29 PL PL09738185T patent/PL2282778T3/pl unknown
- 2009-04-29 JP JP2011506707A patent/JP5721230B2/ja active Active
- 2009-04-29 AU AU2009242126A patent/AU2009242126B2/en active Active
- 2009-04-29 EA EA201071244A patent/EA021731B1/ru not_active IP Right Cessation
- 2009-04-29 ES ES09738185.9T patent/ES2622504T3/es active Active
- 2009-04-29 KR KR1020107026061A patent/KR101660401B1/ko active IP Right Grant
- 2009-04-29 BR BRPI0911520A patent/BRPI0911520A2/pt not_active Application Discontinuation
- 2009-04-29 PT PT97381859T patent/PT2282778T/pt unknown
- 2009-04-29 NZ NZ589307A patent/NZ589307A/en not_active IP Right Cessation
- 2009-04-29 WO PCT/EP2009/055205 patent/WO2009133141A2/en active Application Filing
- 2009-04-29 EP EP09738185.9A patent/EP2282778B1/en active Active
- 2009-04-29 DK DK09738185.9T patent/DK2282778T3/en active
- 2009-04-29 SI SI200931641A patent/SI2282778T1/sl unknown
- 2009-04-29 HU HUE09738185A patent/HUE033726T2/en unknown
- 2009-04-29 CA CA2722453A patent/CA2722453C/en active Active
- 2009-04-29 CN CN200980122773.4A patent/CN102065898B/zh active Active
-
2010
- 2010-10-28 IL IL208982A patent/IL208982B/en active IP Right Grant
- 2010-10-29 US US12/915,709 patent/US11291670B2/en active Active
- 2010-11-10 ZA ZA2010/08037A patent/ZA201008037B/en unknown
-
2017
- 2017-04-03 HR HRP20170531TT patent/HRP20170531T1/hr unknown
- 2017-04-13 CY CY20171100439T patent/CY1118956T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5721230B2 (ja) | 2015-05-20 |
| LT2282778T (lt) | 2017-06-26 |
| MX2010011881A (es) | 2011-07-01 |
| DK2282778T3 (en) | 2017-05-01 |
| KR20110010734A (ko) | 2011-02-07 |
| BRPI0911520A2 (pt) | 2017-06-13 |
| EA021731B1 (ru) | 2015-08-31 |
| AU2009242126B2 (en) | 2014-03-27 |
| CA2722453A1 (en) | 2009-11-05 |
| AU2009242126A1 (en) | 2009-11-05 |
| CA2722453C (en) | 2018-03-20 |
| HUE033726T2 (en) | 2017-12-28 |
| US11291670B2 (en) | 2022-04-05 |
| WO2009133141A2 (en) | 2009-11-05 |
| PT2282778T (pt) | 2017-04-27 |
| ZA201008037B (en) | 2011-08-31 |
| NZ589307A (en) | 2012-04-27 |
| EA201071244A1 (ru) | 2011-06-30 |
| EP2282778A2 (en) | 2011-02-16 |
| ES2622504T3 (es) | 2017-07-06 |
| CN102065898A (zh) | 2011-05-18 |
| SI2282778T1 (sl) | 2017-07-31 |
| IL208982B (en) | 2018-03-29 |
| PL2282778T3 (pl) | 2017-08-31 |
| JP2011518864A (ja) | 2011-06-30 |
| CN102065898B (zh) | 2015-08-26 |
| CY1118956T1 (el) | 2018-01-10 |
| IL208982A0 (en) | 2011-01-31 |
| WO2009133141A3 (en) | 2009-12-30 |
| KR101660401B1 (ko) | 2016-09-27 |
| US20120058992A1 (en) | 2012-03-08 |
| EP2282778B1 (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170531T1 (hr) | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| JP2013520405A5 (hr) | ||
| JP2010222367A5 (hr) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| JP2013542247A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| JP2016185995A5 (hr) | ||
| HRP20150375T1 (hr) | Derivati piridazinona | |
| JP2015523407A5 (hr) | ||
| NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| JP2013231087A5 (hr) | ||
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| JP2008044951A5 (hr) | ||
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| JP2014050390A5 (hr) | ||
| JP2015501783A5 (hr) | ||
| JP2009500045A5 (hr) | ||
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| JP2013541583A5 (hr) | ||
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof |